LINCOLN PHARMACEUTICALS LTD – EMERGING HEALTHCARE COMPANY WITH A ROBUST GROWTH OUTLOOK
Lincoln Pharmaceuticals Limited, a prominent player in India's healthcare sector, has continued to demonstrate impressive operational and financial prowess over the years and emerged as a company to watch out for over the next few years. Company aims to maintain healthy growth in revenue and margins in the coming years and has set a target of achieving Rs. 750 crore revenue by FY26 while maintaining its ‘Net Debt Free’ status.
With over 1,700 registered products and 700 more in development, company is focused on innovating and expanding its portfolio. Future plans include bolstering offerings in lifestyle, chronic, women's healthcare, and dermatology segments alongside its existing acute care presence. In FY23, it introduced 18 products domestically and submitted 130+ export dossiers.
As of December 2023, Foreign Institutional Investors (FIIS) have steadily raised their holding in the company to 3.22%. FII holding in the company as on December 2022 was 1.44%. Company is also ranked among a very few companies (Top 16 out of 4,200 plus listed companies in the Indian stock exchange) to achieve a profit growth every single year from FY13 to FY23 as per the analysis of Morningstar. During the decade, company has delivered a robust CAGR of over 22% in Net profits, 19% plus in EBITDA and over 10% in Revenue.
Company reported its Best-ever results in FY23 with highest - Revenue, EBITDA and Net Profit. It achieved milestone of Rs. 500 crore plus revenue and Rs. 100 crore plus Profit Before Tax (PBT) for the first time in a financial year. During nine months of current fiscal FY24, company beat its past growth numbers with Y-O-Y growth of 11.8% in revenue, 19.6% in EBITDA and 23.8% in Net Profit. It surpassed PBT of Rs. 100 crores during 9M FY24 which it reported for the full of FY23.
Mr. Mahendra Patel, Managing Director, said, “We anticipate even stronger growth in the future through upcoming product launches in domestic and export markets, improved operational efficiency, and the introduction of higher-margin products. With our steadfast growth strategies, expansion plans for products and markets, and focus on operational efficiency, we are targeting revenue of Rs. 750 crore in FY26.”
The company has finished expanding its Cephalosporin plant in Mehsana, Gujarat, and has started commercial production. It aims to register the product for export to multiple countries, expecting sales of around Rs. 150 crore in the next 3 years.
Company exports to 60+ countries spanning East & West Africa, Central & Latin America, and Southeast Asia. New exports to Canada have begun, and with approvals from TGA (Australia) and EU GMP, the company plans to expand its reach to 90+ countries, strengthening its global footprint. Company has state-of-the-art manufacturing facility units at Khatraj in Ahmedabad and Mehsana, Gujarat with a stringent international quality and compliance norms. The company has crafted 600+ formulations across 15 therapeutic areas, boasting a robust brand lineup in areas such as antiinfective, respiratory, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, and anti-malaria. Additionally, it has filed over 25 patent applications and received seven patents.